Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With <scp>COVID</scp> ‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

Tim Rowland, Richard FitzGerald, Elizabeth Challenger, Laura Dickinson, Laura J. Else, Lauren Walker, Colin Hale, Victoria Shaw, Callum Kelly, Rebecca Lyon, Jennifer Gibney, Karim Dhamani, Margaret Irwin, Yvanne Enever, Michelle Tetlow, William Wood, Helen Reynolds, Justin Chiong, Orod Osanlou, Henry Pertinez, Katie Bullock, William Greenhalf, Andrew Owen, David G. Lalloo, Michael Jacobs, Julian A. Hiscox, Thomas Jaki, Pavel Mozgunov, Geoffrey Saunders, Gareth Griffiths, Saye H. Khoo, Thomas E. Fletcher, Unknown

Open source

DOI: 10.1002/cpt.70261
Published: 2026-03-18
Container: Clinical Pharmacology & Therapeutics
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cpt.70261,
  title = {Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With
                    <scp>COVID</scp>
                    ‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study},
  author = {Tim Rowland and Richard FitzGerald and Elizabeth Challenger and Laura Dickinson and Laura J. Else and Lauren Walker and Colin Hale and Victoria Shaw and Callum Kelly and Rebecca Lyon and Jennifer Gibney and Karim Dhamani and Margaret Irwin and Yvanne Enever and Michelle Tetlow and William Wood and Helen Reynolds and Justin Chiong and Orod Osanlou and Henry Pertinez and Katie Bullock and William Greenhalf and Andrew Owen and David G. Lalloo and Michael Jacobs and Julian A. Hiscox and Thomas Jaki and Pavel Mozgunov and Geoffrey Saunders and Gareth Griffiths and Saye H. Khoo and Thomas E. Fletcher and Unknown},
  year = {2026},
  journal = {Clinical Pharmacology \&amp; Therapeutics},
  doi = {10.1002/cpt.70261},
  url = {https://doi.org/10.1002/cpt.70261}
}

RIS

TY  - JOUR
TI  - Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With
                    <scp>COVID</scp>
                    ‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study
AU  - Tim Rowland
AU  - Richard FitzGerald
AU  - Elizabeth Challenger
AU  - Laura Dickinson
AU  - Laura J. Else
AU  - Lauren Walker
AU  - Colin Hale
AU  - Victoria Shaw
AU  - Callum Kelly
AU  - Rebecca Lyon
AU  - Jennifer Gibney
AU  - Karim Dhamani
AU  - Margaret Irwin
AU  - Yvanne Enever
AU  - Michelle Tetlow
AU  - William Wood
AU  - Helen Reynolds
AU  - Justin Chiong
AU  - Orod Osanlou
AU  - Henry Pertinez
AU  - Katie Bullock
AU  - William Greenhalf
AU  - Andrew Owen
AU  - David G. Lalloo
AU  - Michael Jacobs
AU  - Julian A. Hiscox
AU  - Thomas Jaki
AU  - Pavel Mozgunov
AU  - Geoffrey Saunders
AU  - Gareth Griffiths
AU  - Saye H. Khoo
AU  - Thomas E. Fletcher
AU  - Unknown
PY  - 2026
JO  - Clinical Pharmacology &amp; Therapeutics
DO  - 10.1002/cpt.70261
UR  - https://doi.org/10.1002/cpt.70261
ER  -

APA

Rowland, T., FitzGerald, R., Challenger, E., Dickinson, L., Else, L. J., Walker, L., Hale, C., Shaw, V., Kelly, C., Lyon, R., Gibney, J., Dhamani, K., Irwin, M., Enever, Y., Tetlow, M., Wood, W., Reynolds, H., Chiong, J., Osanlou, O., Pertinez, H., Bullock, K., Greenhalf, W., Owen, A., Lalloo, D. G., Jacobs, M., Hiscox, J. A., Jaki, T., Mozgunov, P., Saunders, G., Griffiths, G., Khoo, S. H., Fletcher, T. E., & Unknown (2026). Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With <scp>COVID</scp> ‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70261

Source records

crossref · retrieved 2026-09-27T14:56:49.096Z